FDA stamp of approval

FDA Approves Darolutamide, Docetaxel Combination for Metastatic Hormone-Sensitive Prostate Cancer

The FDA has approved a supplemental new drug application for darolutamide in combination with docetaxel for patients with metastatic hormone-sensitive prostate cancer.
Advertisement

The Uromigos - A Podcast

Expert Interviews

PSMA Knowledge Hub

Curated Journal reading List

Advertisement